Table 4 Studies having evaluated herpes simplex virus and/or cytomegalovirus reactivations in COVID-19 patients
Study | Population | Immunosuppresssion | HSV detection | CMV detection | Mortality | ||
|---|---|---|---|---|---|---|---|
Blood | LRT | Blood | LRT | ||||
Franceschini [7] | 70 patients 23 (33%) on IMV | 3 (4.3%) | 21 (30%) | – | 29 (41%) | – | 15 (21.4%) |
Simmonet [8] | 34 patients 30 (88%) on IMV | 2 (6%) | – | – | 5 (15%) | – | 6 (18%) |
Saade [5] | 100 patients 54 (54%) on IMV | 38 (38%) | 12 (12%) | – | 19 (19%) | – | 28 (28%) |
Seeße [6] | 18 patients on IMV | 3 (13.3%) | 1 (7.7%) | 15 (83%) | – | – | NR |
Le Balc’h [10] | 38 patients on IMV | 3 (8%) | – | 16 (42) | – | 9 (24) | 4 (10.5%) |
Meyer [9] | 153 patients 40 on IMV | NR | 36/146 (24.7%) | 19/61 (31.1%) | – | – | 57 (37.3%) |
Luyt, present study | 145 patients on IMV 144 on ECMO | 12 (8%) | 5/19 (26%) | 73 (50%) | 15/29 (52%) | 61 (42%) | 63 (43%) |